Therapy treatment options for psoriasis: Topical and systemic

Therapy

Volumn 1, Issue 2, 2004, Pages 319-330

  Mikhail, Maryann ^a   Scheinfeld, Noah S ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Acetretin; Anthralin; Biologic; Biological therapy; Cyclosporin; Methotrexate; Psoriasis; Topical corticosteroids

Indexed keywords

ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; DIFLORASONE DIACETATE; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; FLUOROURACIL; HYDROCORTISONE; HYDROXYUREA; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN; SALAZOSULFAPYRIDINE; SORIATAINE; TAR; TAZAROTENE; TIOGUANINE; TRIETHANOLAMINE; TUMOR NECROSIS FACTOR ALPHA; ULOBETASOL PROPIONATE; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; BONE MARROW TOXICITY; CALCIFICATION; CANCER RISK; CHEILITIS; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTACT DERMATITIS; CYTOPENIA; DEMYELINATING DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; HAIR LOSS; HEADACHE; HISTOPATHOLOGY; HISTOPLASMOSIS; HUMAN; HYPERCALCEMIA; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERTENSION; HYPERTRICHOSIS; IMMUNE DEFICIENCY; INJECTION SITE REACTION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG TOXICITY; LYMPHOCYTOPENIA; LYMPHOMA; MACROCYTIC ANEMIA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PERMISSIBLE DOSE; MELANOMA; MYALGIA; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PARESTHESIA; PATHOGENESIS; PHOTOSENSITIVITY; PHOTOTHERAPY; PRURITUS; PSORIASIS; PYOGENIC GRANULOMA; RELAPSE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN TOXICITY; STOMATITIS; SUN EXPOSURE; T LYMPHOCYTE; TACHYPHYLAXIS; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT PLANNING; TUBERCULOSIS; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 23944485998     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.1.2.319     Document Type: Review

References (71)

1. Fitzpatrick T, Johnson R, Wolff K, Suurmond D. In: Color Atlas & Synopsis of Clinical Dermatology. McGraw Hill, Boston, USA 50-69 (2001).
2. Lui H, Mamelak A. Plaque psoriasis. Emedicine, 2000 (2004).
3. Greaves M, Weinstein G. Treatment of psoriasis. N. Engl. J. Med. 332, 581-588 (1995).
4. Bowcock A, Barker J. Genetics of psoriasis: the potential impact on new therapies. J. Am. Stern R. Psoriasis. Lancet 350, 349-353 (1997).
5. Ackerman A, Kerl H, Sanchez J. et al. In: A clinical atlas of 101 common skin diseases with histopathologic correlation. Ardor Scribendi, NY, USA 494-512 (2000).
6. Lebwohl M, Heymann W, Berth-Jones J, Coulson I. In: Treatment of Skin Disease. Mosby, NY, USA 533-540 (2002).
7. Peters B, Weissman F, Gill M. Pathophysiology and treatment of psoriasis. Am. J. Health-Pharmacy 57, 645-662 (2000).
8. Lebwohl M, Ali M. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J. Am. Acad. Dermatol. 45, 487-498 (2001).
9. Runne U, Kunze J. Short duration ('minutes') therapy with dithranol for psoriasis: A new out-patient regimen. Br. J. Dermatol. 106, 135-139 (1982).
10. Thune P, Brolund L. Short and long contact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis. Acta Derm. Venereol. (Suppl. 172), 28-29 (1992).
11. Ramsay B, Lawrence C, Bruce J, Shuster S. The effects of trimethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J. Am. Acad. Dermatol. 23, 73-6 (1990).
12. Liem W, McCullough J, Weinstein G. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 55, 306-310 (1995).
13. Cornell R, Stoughton R. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch. Dermatol. 121, 63-67 (1985).
14. Linden K, Weinstein G. Psoriasis: Current perspectives with an Emphasis on Treatment. Am. J. Med. 107 (1999).
15. Katz H, Hien N, Prawer S, Mastbaum L, Mooney J, Samson C. Superpotent topical steroid treatment of psoriasis vulgaris, clinical efficacy and adrenal function. J. Am. Acad. Dermatol. 16, 804-811 (1987).
16. Takeda K, Arase S, Takahashi S. Side effects of topical corticosteroids and their prevention. Drugs 36, 15-23 (1988).
17. Franz T, Parsell D, Halualani R, Hannigan J, Kalbach J, Harkonen W. Betamethasone valerate foam 0.12% a novelvehicle with enhanced delivery and efficacy. Int. J. Dermatol. 38, 628-632 (1999).
18. Kragballe K. Treatment of psoriasis by topical application of the novel vitamin D3 analog calcipotriol MC 903. Arch. Dermatol.. 125, 1647-1652 (1989).
19. Dubertret L, Wallach D, Souteyrand P et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J. Am. Acad. Dermatol. 27, 983-988 (1992).
20. Kragballe K, Gjertsen B, De Hoop D et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 337, 193-196 (1991).
21. Cunliffe W, Berth-Jones J, Claudy A et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J. Am. Acad. Dermatol.. 26, 736-743 (1992).
22. Kragballe K, Fogh K, Sogaard H. Long-term efficacy and tolerability of topical calcipotriol in psoriasis. Results of an open study. Acta. Derm. Venereol. (Suppl.71), 475-478 (1991).
23. Bruce S, Epinette W, Funicella T, Ison A, Jones E, R L. Comparative study of calipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J. Am. Acad. Dermatol.. 31, 755-759 (1994).
24. Lebwohl M, Siskin S, Epinette W et al. A multicenter trial of calcipotriene ointment and halobetasol ointment to either agent alone for the treatment of psoriasis. J. Am. Acad. Dermatol.. 35, 268-269 (1996).
25. Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene and halobetasol ointment in the long term treatment of psoriasis: effects on the duration of improvement. J. Am. Acad. Dermatol. 39, 447-450 (1998).
26. Weinstein G, Krueger G, Lowe N. Tazarotene gel, a new retinoid for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J. Am. Acad. Dermatol. 37, 85-92 (1997).
27. Lebwohl M, Ast E, Callen J. Once daily tazarotene gel versus twice daily fluocinide cream in the treatment of plaque psoriasis. J. Am. Acad. Dermatol. 38, 705-711 (1998).
28. Weinstein GD, Koo J, Krueger GG et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of hte safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J. Am. Acad. Dermatol.. 48, 760-767 (2003).
29. Lebwohl M, Breneman D et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J. Am. Acad. Dermatol. 39, 590-596 (1998).
30. Kaidbey K, Kopper S, Sefton J, Gibson J. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int. J. Dermatol. 40, 468-471 (2001).
31. Coven T, Burack L, Gilleaudeau P, Keogh M, Ozawa M, Krueger J. Narrowband UV-B produces superior clinical and histopathological resulotion of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch. Dermatol.. 133, 1514-1522 (1997).
32. Walters I, Burack L, Coven T, Gilleaudeau P. Krueger GG. Suberethmogenic narrowband UVB is markedly more effective than convential UVB in the treatment of psoriasis vulgaris. J. Am. Acad. Dermatol. 40, 893-900 (1999).
33. Molin L. Topical calcipotriol combined with phototherapy for psoriasis: the results of two randomized trials and a review of the literature. Dermatology 198 (1999).
34. Koo J, Behnam S, Behnam S. The efficacy of tazarotene monotherapy and combination therapies in psoriasis. Expert Opin. Pharmacother. 4, 2347-2354 (2003).
35. Trehan M, Taylor C. High-dose 308-nm excimer laser for the treatment of psoriasis. J. Am. Acad. Dermatol.. 46, 732-737 (2002).
36. Asawanonda P, Anderson R, Chang Y, Taylor C. 308-nm excimer laser for the treatment of psoriasis: a dose-response study. Arch. Dermatol. 136, 619-624 (2000).
37. Feldman S, Mellen B, Housman T et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicener study. J. Am. Acad. Dermatol. 46, 900-906 (2002).
38. Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. 1977. J. Invest. Dermatol. 92, 153S; discussion 154S-156S (1989).
39. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J. Am. Acad. Dermatol. 41, 51-59 (1999).
40. Stern R, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J. Am. Acad. Dermatol. 92, 120-4 (1988).
41. Stern R, Nichols K, Vakeva L. Malignant in melanoma in patients treated for psoriasis with methoxsalen (Psoralen) and ultraviolet-A radiation (PUVA). N. Engl. J. Med. 336, 1041-1045 (1997).
42. Speight E, Farr P. Calcipotriol improves the response of psoriasis to PUVA. Br. J. Dermatol. 130, 79-82 (1994).
43. Tzaneva S, Honigsmann H, Tanew A, Seeber A. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br. J. Dermatol. 147, 748-53 (2002).
44. Stern R, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 73, 2759-2764 (1994).
45. Paul C, Ho V, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J. Invest. Dermatol. 120, 211-216 (2003).
46. Lebwohl M, Ali M. Treatment of psoriasis. Part 2. Systemic therapies. J. Am. Acad. Dermatol. 45 (2001).
47. Tanew A, Guggenbichler A, Honigsmann H, Geiger J, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J. Am. Acad. Dermatol. 25, 682-684 (1991).
48. Lowe N, Prystowsky J, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J. Am. Acad. Dermatol. 24, 591-594 (1991).
49. Lebwohl M, Tannis C, Carrasco D. Acitretin suppression of squamous cell carcinoma: case report and literature review. J. Dermatolog. Treat. 14, 3-6 (2003).
50. Anstey A, Hawk J. Isotreinoin-PUVA in women with psoriasis. Br. J. Dermatol. 136, 798-9 (1997).
51. Van Dooren-Greebe R, Kuijpers A, Mulder J, DeBoo T, Van de Kerhof P. Methotrexate revisited: effects of long-term treatment in psoriasis. Br. J. Dermatol. 130, 204-210 (1994).
52. Roenigk HJ, Auerbach R, Maibach H, Weinstein G. Methotrexate in psoriasis: revised guidelines. J. Am. Acad. Dermatol. 19, 145-156 (1988).
53. Shupack J, Abel E, Bauer E et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J. Am. Acad. Dermatol. 36, 423-432 (1997).
54. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med. 349, 658-665 (2003).
55. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L. Long-term safety of cyclosporine in the treatment of psoriasis. Arch. Dermatol. 132, 623-629 (1996).
56. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin. Ther. 25, 2487-2505 (2003).
57. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 47, 821-33 (2002).
58. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. 139, 719-727 (2003).
59. Ortonne JP, Lebwohl M, Em Griffiths C. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur. J. Dermatol. 13, 117-123 (2003).
60. Gottlieb A, Krueger J, Bright R et al. Effects of administration of a single dose of humanized monoclonal antibody to CD11a on the immunology and clinical activity of psoriasis. J. Am. Acad. Dermatol. 42, 428-435 (2000).
61. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Wilicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch. Dermatol. 138, 591-600 (2002).
62. Papp K, Bissonnette R, Krueger JG et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J. Am. Acad. Dermatol. 45, 665-674 (2001).
63. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349, 2004-2013 (2003).
64. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290, 3073-3080 (2003).
65. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 385-390 (2000).
66. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139, 1627-1632 (2003).
67. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-22 (2003).
68. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357, 1842-1847 (2001).
69. Gottlieb AB, Masud S, Ramamurthi R et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48, 68-75 (2003).
70. Scheinfeld N. The use of topical tacrolimus and pimercolimus in psoriasis: A review. Dermatol Online J. 10 (2004).
71. Walker P, Gottlieb A, Guenther L, Kang S, King L, Koo J. Oral tazarotene (4.5mg capsule) in patients with moderate to severe plaque psoriasis. Am. Acad. Dermatol. IL, USA July 25-29 (2003).